Abogen Biosciences

Abogen is a discovery stage biotechnology company focused on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Abogen Biosciences' pipeline covers a variety of oncology drugs and infectious disease vaccine products.

Abogen Biosciences was founded in 2019 by Bo Ying. The company is headquartered in Suzhou, China.


Abogen has an industry-leading mRNA and nano-delivery technology platform with independent intellectual property rights. The company has built extensive product pipelines, ranging from infectious disease prevention and treatment to tumor immunity.


Abogen was engaged with the COVID-19 mRNA vaccine project in Jun 2021, of the Academy of Military Medical Sciences (AMMS) of the PLA Academy of Military Science and Walvax Biotechnology, and succeeded to obtain the NMPA clinical trial approval by joint efforts.


Abogen was the first mRNA vaccine approved for clinical trial in China. The vaccine has gone through Phase I and Phase II clinical trials and is now undergoing Phase III clinical trials.


Abogen is backed by Temasek, SoftBank Vision Fund, Invesco Developing Markets Fund, 5Y Capital, Qiming Venture Partners, Highlight Capital, Loyal Valley Capital, GL Ventures, Yunfeng Capital, Lilly Asia Ventures, and others. The company raised $300M in Series C+ round on Nov 29, 2021. This brings Abogen's total funding to $1.1B to date.



  • Year founded: 2019
  • Funding Info: $1.1B over 4 Rounds (Latest Funding Type: Series C+)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Suzhou
  • State: Jiangsu
  • Country: China
Related businesses